Diligence memo · auto-generated · as of July 2, 2026

Ramona Optics, Inc.

Ramona Optics, Inc. looks fair against its niche peers and is active on financing cadence.

SourceRaising on rhythm with a 65.1× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

Ramona Optics, Inc. operates in Biotechnology, based in DURHAM.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Ramona Optics, Inc. has raised $28M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $26M on 2026-02-25.

Most recent recorded round closed around 2026-02-25.

Valuation (modeled)modeled

Provath models Ramona Optics, Inc. at approximately $91M (range $52M–$119M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.18× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era. Within the normal band (118% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 31 months.

Last raise 4 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

The last round stepped up 65.1× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 73% of Biotechnology peers (4293 compared).

Modeled value ranks above 57% of those peers.

Closest niche peers: MarvelBiome, Inc., Iantrek, Inc., Dualitas Therapeutics, Inc., Antares Therapeutics, Inc., OrthoBio Therapeutics, Inc..

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.